These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2452774)

  • 1. Comparison of serum CA-125 and lipid-associated sialic acid (LASA-P) in monitoring patients with invasive ovarian adenocarcinoma.
    Patsner B; Mann WJ; Vissicchio M; Loesch M
    Gynecol Oncol; 1988 May; 30(1):98-103. PubMed ID: 2452774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma lipid-associated sialic acid and serum CA 125 as indicators of disease status with advanced ovarian cancer.
    Vardi JR; Tadros GH; Foemmel R; Shebes M
    Obstet Gynecol; 1989 Sep; 74(3 Pt 1):379-83. PubMed ID: 2761915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The utility of lipid-associated sialic acid (LASA or LSA) as a serum marker for malignancy. A review of the literature.
    Schutter EM; Visser JJ; van Kamp GJ; Mensdorff-Pouilly S; van Dijk W; Hilgers J; Kenemans P
    Tumour Biol; 1992; 13(3):121-32. PubMed ID: 1626178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid associated sialic acid in plasma in patients with advanced carcinoma of the ovaries.
    Vardi JR; Tadros GH; Malhotra C; Charney T; Shebes M; Foemmel R
    Surg Gynecol Obstet; 1989 Apr; 168(4):296-301. PubMed ID: 2928903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian cancer and tumor markers: sialic acid, galactosyltransferase and CA-125.
    Goldhirsch A; Berger E; Müller O; Maibach R; Misteli S; Buser K; Roesler H; Brunner K
    Oncology; 1988; 45(4):281-6. PubMed ID: 3133621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease?
    Patsner B; Orr JW; Mann WJ; Taylor PT; Partridge E; Allmen T
    Gynecol Oncol; 1990 Jun; 37(3):319-22. PubMed ID: 2190870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease?
    Patsner B; Orr JW; Mann WJ; Taylor PT; Partridge E; Allmen T
    Gynecol Oncol; 1990 Sep; 38(3):373-6. PubMed ID: 2227551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of lipid-associated sialic acid and CA 19-9 as tumor markers for renal cell carcinoma.
    Echenique JE; Graham SD
    Urology; 1988 Nov; 32(5):397-400. PubMed ID: 3188302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CA 125, NB/70K, and lipid-associated sialic acid in monitoring uterine papillary serous carcinoma.
    Tseng PC; Sprance HE; Carcangiu ML; Chambers JT; Schwartz PE
    Obstet Gynecol; 1989 Sep; 74(3 Pt 1):384-7. PubMed ID: 2761916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of three tumor markers--CA-125, lipid-associated sialic acid (LSA), and NB/70K--in monitoring ovarian cancer.
    Petru E; Sevin BU; Averette HE; Koechli OR; Perras JP; Hilsenbeck S
    Gynecol Oncol; 1990 Aug; 38(2):181-6. PubMed ID: 2387533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of serum markers in the diagnosis and management of laryngeal cancer.
    Mevio E; Benazzo M; Galioto P; Spriano P; Pizzala R
    Clin Otolaryngol Allied Sci; 1991 Feb; 16(1):90-2. PubMed ID: 2032368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum CA-125 as a guideline for the timing of a second-look operation and second-line treatment in ovarian cancer.
    Jäger W; Adam R; Wildt L; Lang N
    Arch Gynecol Obstet; 1988; 243(2):91-9. PubMed ID: 2456743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor debulking followed by immediate combination chemotherapy in advanced ovarian carcinoma. Phase II.
    Vardi JR; Tadros GH; Zamurovic D; Rafla SD
    Acta Obstet Gynecol Scand; 1992 Jul; 71(5):361-7. PubMed ID: 1326212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of fluctuation of serum tumor markers in advanced cancer of prostate.
    Maatman TJ
    Urology; 1993 Dec; 42(6):672-6. PubMed ID: 7504849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid-associated sialic acid, squamous cell carcinoma antigen, carcinoembryonic antigen, and lactic dehydrogenase levels as tumor markers in squamous cell carcinoma of the head and neck.
    Dreyfuss AI; Clark JR; Andersen JW
    Cancer; 1992 Nov; 70(10):2499-503. PubMed ID: 1423179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CA 15-3 serum levels in ovarian cancer.
    Scambia G; Benedetti Panici P; Baiocchi G; Perrone L; Greggi S; Di Roberto P; Mancuso S
    Oncology; 1988; 45(3):263-7. PubMed ID: 3163419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved procedure for determination of serum lipid-associated sialic acid: application for early diagnosis of colorectal cancer.
    Tautu C; Verazin G; Prorok JJ; Alhadeff JA
    J Natl Cancer Inst; 1988 Oct; 80(16):1333-7. PubMed ID: 3172258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tumor markers in the monitoring of ovarian cancer].
    Xu SX
    Zhonghua Fu Chan Ke Za Zhi; 1990 Nov; 25(6):345-7, 383. PubMed ID: 2282861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individual and combined usefulness of lipid associated sialic acid, mucoid proteins and hexoses as tumor markers in breast carcinoma.
    Patel PS; Baxi BR; Adhvaryu SG; Balar DB
    Cancer Lett; 1990 Jun; 51(3):203-8. PubMed ID: 2161706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary gonadotropin fragments (UGF) in cancers of the female reproductive system. I. Sensitivity and specificity, comparison with other markers.
    Cole LA; Schwartz PE; Wang YX
    Gynecol Oncol; 1988 Sep; 31(1):82-90. PubMed ID: 3044936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.